Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study
- PMID: 11586052
- DOI: 10.1159/000054932
Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study
Abstract
We investigated the relationships between extrapyramidal symptoms (EPS) induced by risperidone, the dosage of risperidone and the combined plasma concentrations of risperidone plus its active metabolite, 9-hydroxyrisperidone, in 20 schizophrenic patients. There was a positive correlation between the scores on the Simpson and Angus Scale and both the dosage of risperidone and the sum of the plasma levels of risperidone and 9-hydroxyrisperidone. These results suggest that EPS induced by risperidone increase in conjunction with both the dosage of risperidone and the total plasma concentrations of the parent compound and its active metabolite.
Copyright 2001 S. Karger AG, Basel
Similar articles
-
Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.J Pharm Biomed Anal. 1999 Mar;19(3-4):595-601. doi: 10.1016/s0731-7085(98)00261-1. J Pharm Biomed Anal. 1999. PMID: 10704125 Clinical Trial.
-
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.Psychopharmacology (Berl). 2001 Jan 1;153(2):238-43. doi: 10.1007/s002130000576. Psychopharmacology (Berl). 2001. PMID: 11205425 Clinical Trial.
-
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.Int Clin Psychopharmacol. 2005 Mar;20(2):71-8. doi: 10.1097/00004850-200503000-00002. Int Clin Psychopharmacol. 2005. PMID: 15729081
-
Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.Ther Drug Monit. 2003 Jun;25(3):287-93. doi: 10.1097/00007691-200306000-00006. Ther Drug Monit. 2003. PMID: 12766554
-
Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?Ther Drug Monit. 2011 Jun;33(3):275-83. doi: 10.1097/FTD.0b013e3182126d83. Ther Drug Monit. 2011. PMID: 21436762 Review.
Cited by
-
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.Innov Clin Neurosci. 2012 Jul;9(7-8):17-23. Innov Clin Neurosci. 2012. PMID: 22984648 Free PMC article.
-
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.Clin Ther. 2007 Jul;29(7):1476-86. doi: 10.1016/j.clinthera.2007.07.026. Clin Ther. 2007. PMID: 17825699 Free PMC article. Clinical Trial.
-
Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review.Pharmaceuticals (Basel). 2025 May 8;18(5):698. doi: 10.3390/ph18050698. Pharmaceuticals (Basel). 2025. PMID: 40430517 Free PMC article. Review.
-
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.Br J Clin Pharmacol. 2004 May;57(5):569-75. doi: 10.1111/j.1365-2125.2003.02061.x. Br J Clin Pharmacol. 2004. PMID: 15089809 Free PMC article.
-
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.Eur J Clin Pharmacol. 2010 Nov;66(11):1109-17. doi: 10.1007/s00228-010-0850-1. Epub 2010 Jun 19. Eur J Clin Pharmacol. 2010. PMID: 20563569
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical